Business
Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases
In two non-GLP studies, CUE-401 was well tolerated with no adverse events observed Proof-of-concept studies reinforce promising preclinical profile and therapeutic potential of CUE-401 BOSTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced pre
About this update from Cue Biopharma, Inc.
[{"type":"image","alt":"Cue Biopharma, Inc.","displaySize":"","headline":null,"caption":"Cue Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/2e66156a6e123e96f63fe86db58bbe09"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/btk.uQvFNhbkAb9kiEpvZA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2e66156a6e123e96f63fe86db58bbe09","width":300,"height":110}},"lazy":false},{"type":"text","content":"In two non-GLP studies, CUE-401 was well tolerated with no adverse events observed","length":82,"tagName":"p"},{"type":"text","content":"Proof-of-concept studies reinforce promising preclinical profile and therapeutic potential of CUE-401 ","length":101,"tagName":"p"},{"type":"text","content":"BOSTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced preclinical safety and tolerability data that further supports the preclinical profile of CUE-401, the Company’s lead autoimmune asset.","length":452,"tagName":"p"},{"type":"text","content":"“We are very encouraged with this preclinical data, which demonstrated that CUE-401 was well tolerated, and no adverse events were observed,” said Usman Azam, M.D., president and chief executive officer of Cue Biopharma. “Data generated from these preclinical studies represent an important addition to the growing evidence supporting the potential of CUE-401 as a first-in-class bifunctional tolerogenic agent for the treatment of autoimmune disease. We look forward to sharing further scientific data and details on the planned investigational new drug (IND) filing for CUE-401 in the upcoming months.”","length":604,"tagName":"p"},{"type":"text","content":"Study design and key data highlights include:Two separate non-GLP studies in mice and non-human primates (NHPs) assessed the safety and tolerability of CUE-401 using a step-up dosing schedule, where animals successively received higher doses of CUE-401, weekly. CUE-401 was administered intravenously.","length":302,"tagName":"p"},{"type":"text","content":"Murine Study (n=24, ...